Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T13:43:00.209Z.
Calculation as of: 2026-10-06T13:43:00.209Z.
Quote observation: 2026-10-06T13:39:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc00e8cb63dba40c56ed5fb80588e73c180b52fe93b8081d2416c5f575d95e45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$120.80M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$119.09M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$118.52M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$117.03M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$123.26M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.84M
Operating Cash Flow Yield
N/A
TTM Avg
66.47%
3Y Avg
66.47%
5Y Avg
66.47%
Market Cap
$115.66M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.76M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.47M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $120.80M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $119.09M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $117.03M | N/A | N/A | N/A | N/A |
| enGene Holdings Inc. (ENGN)vs › | $123.26M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.84M | N/A | 66.47% | 66.47% | 66.47% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $114.47M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $111.89M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
